Looking Under the Hood at Shares of Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY)

Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY) has a current MF Rank of 13893. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

Shifting gears, we can see that Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY) has a Q.i. Value of 65.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.

Watching some historical volatility numbers on shares of Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), we can see that the 12 month volatility is presently 92.056200. The 6 month volatility is 56.457700, and the 3 month is spotted at 57.004800. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period. 

At the time of writing, Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY) has a Piotroski F-Score of 2. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

Investors may be interested in viewing the Gross Margin score on shares of Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY). The name currently has a score of 58.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.

The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a company through a combination of dividends, share repurchases and debt reduction.  The Shareholder Yield of Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY) is -0.008083.  This percentage is calculated by adding the dividend yield plus the percentage of shares repurchased.  Dividends are a common way that companies distribute cash to their shareholders.  Similarly, cash repurchases and a reduction of debt can increase the shareholder value, too.  Another way to determine the effectiveness of a company’s distributions is by looking at the Shareholder yield (Mebane Faber).  The Shareholder Yield (Mebane Faber) of Alnylam Pharmaceuticals, Inc. NasdaqGS:ALNY is -0.09104.  This number is calculated by looking at the sum of the dividend yield plus percentage of sales repurchased and net debt repaid yield.